- Home
- / Karyopharm Therapeutics
- / Financials
Karyopharm TherapeuticsHeader placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Financial statements
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 387.0K | 229.0K | 250.0K | 154.0K | 30.3M | 40.9M | 108.1M | 209.8M | |
| Revenue growth, % | -40.8% | 9.2% | |||||||
| General and administrative expense | 5.9M | 15.9M | 21.6M | 23.9M | 24.9M | 48.8M | 105.4M | 126.4M | 143.8M |
| Operating expense total | 34.3M | 76.1M | 119.3M | 110.9M | 132.1M | 210.2M | 227.8M | 277.2M | |
| EBIT | (33.9M) | (75.8M) | (119.1M) | (110.7M) | (130.5M) | (179.9M) | (189.3M) | (171.8M) | (98.3M) |
| EBIT margin, % | -8772.6% | -33120.5% | -47630.4% | -71903.9% | -593.0% | -462.9% | -159.0% | ||
| Interest income | 3.0K | 97.0K | 897.0K | 1.3M | 1.7M | 4.0M | 5.4M | 2.8M | 582.0K |
| Interest expense | 895.0K | 1.3M | 1.6M | 1.5M | 10.3M | ||||
| Pre tax profit | (109.4M) | (128.9M) | (178.4M) | (199.5M) | (196.0M) | (123.8M) | |||
| Income tax expense | (33.9M) | (76.3M) | (118.1M) | 139.0K | 63.0K | 26.0K | 40.0K | 309.0K | 268.0K |
| Net Income | (33.9M) | (75.8M) | (118.2M) | (109.6M) | (129.0M) | (178.4M) | (199.6M) | (196.3M) | (124.1M) |